FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308133265> ?p ?o ?g. }

• W4308133265 endingPage "A608" @default.
• W4308133265 startingPage "A607" @default.
• W4308133265 abstract "Abstract Introduction Clinical signs of puberty, growth rate, rate of bone maturation, luteinizing hormone concentrations and estimates of change in predicted adult height are the common variables for assessing efficacy of central precocious puberty (CPP) therapies. (1, 2) All clinical and laboratory parameters are essential when interpreting treatment response. (3) Preservation of adult height potential is an important goal of CPP treatment and accelerated growth velocity can contribute to reduced adult height. (4) We present secondary analyses of growth velocity data from the pivotal trial of the first small-volume, long-acting, subcutaneously administered GnRH agonist for central precocious puberty (CPP), approved in 2020. (5) Methods: 62 children (60 girls, 2 boys) with treatment-naïve CPP received 2 doses of 45 mg subcutaneous leuprolide acetate at 24-week intervals. We measured standing height with a calibrated stadiometer at Baseline and Weeks 4, 12, 20, 24, 36, 44, and 48. Growth velocity (cm/year) was calculated as a change in height (cm) between visits/((number of weeks between visits)/52). Results Mean growth velocity decreased throughout treatment from 10.4 cm/year for the time period from screening to baseline to 6. 0 cm/year for Week 34 to 48. The proportion of children who achieved growth velocity 4-6 cm/year increased 2.5-fold from baseline (10%) to Week 48 (25%). Conclusions Subcutaneous leuprolide acetate effectively decreased growth velocity to prepubertal rates in children with CPP. Mean growth velocity from Week 24 to 48 was similar to what is seen in children of the same age without CPP (5.8-6.1 cm/year, depending on sex and race). (6) These data indicate that subcutaneous leuprolide acetate may increase adult height and improve the likelihood of achieving genetic target height range. References Cited 1. Klein KO, et al. Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty. JCEM. 2020. 2. Lee HS, et al. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty. PLoS One. 2018. 3. Klein KO, Lee PA. Gonadotropin-releasing hormone (GnRHa) therapy for central precocious puberty (CPP): Review of nuances in assessment of height, hormonal suppression, psychosocial issues, and weight gain, with patient examples. PER. 4. Chen M, Eugster EA. Central Precocious Puberty: Update on Diagnosis and Treatment. Paediatr Drugs. 2015. 5. FENSOLVI® (leuprolide acetate) for injectable suspension, for subcutaneous use [prescribing information]. 2020. 6. Kelly A, et al. Age-based reference ranges for annual height velocity in US children. JCEM. 2014. Presentation: No date and time listed" @default.
• W4308133265 created "2022-11-08" @default.
• W4308133265 creator A5071652964 @default.
• W4308133265 creator A5078005934 @default.
• W4308133265 creator A5080959695 @default.
• W4308133265 date "2022-11-01" @default.
• W4308133265 modified "2023-09-25" @default.
• W4308133265 title "ODP397 Small-volume, Subcutaneous, 6-month Leuprolide Acetate Effectively Reduces Growth Velocity to Prepubertal Levels in Children with Central Precocious Puberty" @default.
• W4308133265 doi "https://doi.org/10.1210/jendso/bvac150.1261" @default.
• W4308133265 hasPublicationYear "2022" @default.
• W4308133265 type Work @default.
• W4308133265 citedByCount "0" @default.
• W4308133265 crossrefType "journal-article" @default.
• W4308133265 hasAuthorship W4308133265A5071652964 @default.
• W4308133265 hasAuthorship W4308133265A5078005934 @default.
• W4308133265 hasAuthorship W4308133265A5080959695 @default.
• W4308133265 hasBestOaLocation W43081332651 @default.
• W4308133265 hasConcept C126322002 @default.
• W4308133265 hasConcept C126894567 @default.
• W4308133265 hasConcept C134018914 @default.
• W4308133265 hasConcept C187212893 @default.
• W4308133265 hasConcept C2778367240 @default.
• W4308133265 hasConcept C2779952775 @default.
• W4308133265 hasConcept C2984496839 @default.
• W4308133265 hasConcept C2991696056 @default.
• W4308133265 hasConcept C71315377 @default.
• W4308133265 hasConcept C71924100 @default.
• W4308133265 hasConcept C89551170 @default.
• W4308133265 hasConceptScore W4308133265C126322002 @default.
• W4308133265 hasConceptScore W4308133265C126894567 @default.
• W4308133265 hasConceptScore W4308133265C134018914 @default.
• W4308133265 hasConceptScore W4308133265C187212893 @default.
• W4308133265 hasConceptScore W4308133265C2778367240 @default.
• W4308133265 hasConceptScore W4308133265C2779952775 @default.
• W4308133265 hasConceptScore W4308133265C2984496839 @default.
• W4308133265 hasConceptScore W4308133265C2991696056 @default.
• W4308133265 hasConceptScore W4308133265C71315377 @default.
• W4308133265 hasConceptScore W4308133265C71924100 @default.
• W4308133265 hasConceptScore W4308133265C89551170 @default.
• W4308133265 hasIssue "Supplement_1" @default.
• W4308133265 hasLocation W43081332651 @default.
• W4308133265 hasLocation W43081332652 @default.
• W4308133265 hasOpenAccess W4308133265 @default.
• W4308133265 hasPrimaryLocation W43081332651 @default.
• W4308133265 hasRelatedWork W1980166143 @default.
• W4308133265 hasRelatedWork W2012606022 @default.
• W4308133265 hasRelatedWork W2014456227 @default.
• W4308133265 hasRelatedWork W2017915411 @default.
• W4308133265 hasRelatedWork W2021502319 @default.
• W4308133265 hasRelatedWork W2079613337 @default.
• W4308133265 hasRelatedWork W2144189739 @default.
• W4308133265 hasRelatedWork W2167129905 @default.
• W4308133265 hasRelatedWork W2959060571 @default.
• W4308133265 hasRelatedWork W3022778455 @default.
• W4308133265 hasVolume "6" @default.
• W4308133265 isParatext "false" @default.
• W4308133265 isRetracted "false" @default.
• W4308133265 workType "article" @default.